UB Paderborn / Katalog / Suche / in CDI

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

The Lancet (British edition), 2020-12, Vol.396 (10267), p.1994-2005

2020

Link zum Volltext

Verfügbarkeit prüfen

Implementation of pre-exposure prophylaxis programme in Spain. Feasibility of four different delivery models

PloS one, 2021-02, Vol.16 (2), p.e0246129-e0246129

2021

Link zum Volltext

Verfügbarkeit prüfen

Monkeypox whitlow: a novel presentation

Clinical and experimental dermatology, 2023-07, Vol.48 (7), p.781-784

2023

Link zum Volltext

Verfügbarkeit prüfen

Clinical and Demographic Features of 49 Patients With Human Monkeypox Virus-Confirmed Infection in a Tertiary Care Center in Valencia, Spain: A Descriptive Study

Sexually transmitted diseases, 2023-02, Vol.50 (2), p.66-73

2023

Link zum Volltext

Verfügbarkeit prüfen

One-step diagnosis strategy together with multidisciplinary telematics referral perform an effective approach for identifying and treating patients with active Hepatitis C infection

Annals of hepatology, 2022-01, Vol.27 (1), p.100542-100542, Article 100542

2022

Link zum Volltext

Verfügbarkeit prüfen

Update on clinical and methodological recommendations for genotypic determination of HIV tropism to guide the usage of CCR5 antagonists

AIDS reviews, 2012-07, Vol.14 (3), p.208-217

2012

Link zum Volltext

Verfügbarkeit prüfen

Genotypic determination of HIV tropism - clinical and methodological recommendations to guide the therapeutic use of CCR5 antagonists

AIDS reviews, 2010-07, Vol.12 (3), p.135-148

2010

Link zum Volltext

Verfügbarkeit prüfen

Acute Myocardial Injury During SARS-CoV-2 Pneumonia and Long-term Prognosis

Journal of general internal medicine : JGIM, 2022-03, Vol.37 (4), p.1014-1016

2022

Link zum Volltext

Verfügbarkeit prüfen

Genotypic tropism testing in proviral DNA to guide maraviroc initiation in aviremic subjects: 48‐week analysis of the PROTEST study

Journal of the International AIDS Society, 2014-11, Vol.17 (4 Suppl 3), p.19520-n/a

2014

Link zum Volltext

Verfügbarkeit prüfen

"I feel empowered": women's perspectives on and experiences with long-acting injectable antiretroviral therapy in the USA and Spain

Culture, health & sexuality, 2021-08, Vol.23 (8), p.1066-1078

2021

Link zum Volltext

Verfügbarkeit prüfen

P-36 RESULTS OF AN AUTOMATIC ALERT SYSTEM FROM MICROBIOLOGY TO LINK DIAGNOSIS TO TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS C

Annals of hepatology, 2023-03, Vol.28, p.100938, Article 100938

2023

Link zum Volltext

Verfügbarkeit prüfen

Maintenance of virologic suppression and improvement in comorbidities after simplification to raltegravir plus boosted darunavir among treatment-experienced HIV-infected patients

International journal of STD & AIDS, 2020-04, Vol.31 (5), p.467-473

2020

Link zum Volltext

Verfügbarkeit prüfen

Abnormal liver chemistry constitutes an independent prognostic factor of less favorable clinical course in patients with COVID-19

Revista española de enfermedades digestivas, 2021-12, Vol.113 (12), p.825

2021

Link zum Volltext

Verfügbarkeit prüfen

News on Viral Hepatitis in HIV: Update from the 2016 GEHEP Conference

AIDS reviews, 2017-01, Vol.19 (1), p.47-53

2017

Link zum Volltext

Verfügbarkeit prüfen

Microangiopatía trombótica en una paciente con infección por el virus de la inmunodeficiencia humana

Infectio : revista de la Asociación Colombiana de Infectología, 2015-10, Vol.19 (4), p.168-171

2015

Link zum Volltext

Verfügbarkeit prüfen

Genetic barrier to resistance for dolutegravir

AIDS reviews, 2015-01, Vol.17 (1), p.56-64

2015

Link zum Volltext

Verfügbarkeit prüfen

Reassessing HIV Detection Strategies: An Analysis of Opportunistic Screening vs. Indicator-Condition-Driven Diagnosis in Valencia, Spain

Journal of community health, 2024-02

2024

Link zum Volltext

Verfügbarkeit prüfen

Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses

The Lancet (British edition), 2022-05, Vol.399 (10339), p.1941-1953

2022

Link zum Volltext

Verfügbarkeit prüfen

Interferon-free therapy for treating hepatitis C virus in difficult-to-treat HIV-coinfected patients

AIDS (London), 2018-01, Vol.32 (3), p.337-346

2018

Link zum Volltext

Verfügbarkeit prüfen

Telaprevir or boceprevir in HIV/HCV‐1 co‐infected patients in a real‐life setting. Interim analysis (24 weeks). COINFECOVA‐SEICV study

Journal of the International AIDS Society, 2014-11, Vol.17 (4 Suppl 3), p.19634-n/a

2014

Link zum Volltext

Verfügbarkeit prüfen

The effects of Maraviroc on liver fibrosis in HIV/HCV co‐infected patients

Journal of the International AIDS Society, 2014-11, Vol.17 (4 Suppl 3), p.19643-n/a

2014

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

Implementation of pre-exposure prophylaxis programme in Spain. Feasibility of four different delivery models

Monkeypox whitlow: a novel presentation

Clinical and Demographic Features of 49 Patients With Human Monkeypox Virus-Confirmed Infection in a Tertiary Care Center in Valencia, Spain: A Descriptive Study

One-step diagnosis strategy together with multidisciplinary telematics referral perform an effective approach for identifying and treating patients with active Hepatitis C infection

Increasing and sustaining blood-borne virus screening in Spain and Portugal throughout the COVID-19 pandemic: a multi-center quality improvement intervention

Update on clinical and methodological recommendations for genotypic determination of HIV tropism to guide the usage of CCR5 antagonists

Genotypic determination of HIV tropism - clinical and methodological recommendations to guide the therapeutic use of CCR5 antagonists

Acute Myocardial Injury During SARS-CoV-2 Pneumonia and Long-term Prognosis

Genotypic tropism testing in proviral DNA to guide maraviroc initiation in aviremic subjects: 48‐week analysis of the PROTEST study

"I feel empowered": women's perspectives on and experiences with long-acting injectable antiretroviral therapy in the USA and Spain

P-36 RESULTS OF AN AUTOMATIC ALERT SYSTEM FROM MICROBIOLOGY TO LINK DIAGNOSIS TO TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS C

Maintenance of virologic suppression and improvement in comorbidities after simplification to raltegravir plus boosted darunavir among treatment-experienced HIV-infected patients

Abnormal liver chemistry constitutes an independent prognostic factor of less favorable clinical course in patients with COVID-19

News on Viral Hepatitis in HIV: Update from the 2016 GEHEP Conference

Microangiopatía trombótica en una paciente con infección por el virus de la inmunodeficiencia humana

Genetic barrier to resistance for dolutegravir

Reassessing HIV Detection Strategies: An Analysis of Opportunistic Screening vs. Indicator-Condition-Driven Diagnosis in Valencia, Spain

Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses

Impact of HIV on the survival of hepatocellular carcinoma in hepatitis C virus-infected patients

Interferon-free therapy for treating hepatitis C virus in difficult-to-treat HIV-coinfected patients

Low performance of ultrasound surveillance for the diagnosis of hepatocellular carcinoma in HIV-infected patients

Hepatocellular carcinoma after sustained virological response with interferon-free regimens in HIV/hepatitis C virus-coinfected patients

Telaprevir or boceprevir in HIV/HCV‐1 co‐infected patients in a real‐life setting. Interim analysis (24 weeks). COINFECOVA‐SEICV study

The effects of Maraviroc on liver fibrosis in HIV/HCV co‐infected patients

Suchergebnisse filtern